Sapropterin dihydrochloride
Pronunciation: Not established in the supplied research notes..
- Generic name
- sapropterin dihydrochloride
- Brand names
- Kuvan
- Drug class
- Synthetic form of tetrahydrobiopterin (BH4); phenylalanine hydroxylase activator
- Form
- Tablet or powder for oral solution
- Route
- Oral
- Legal status
- Not established in the supplied research notes.
Availability and supply rules vary by country
Trade names by country: United States · Canada
Australia: · Full directory
What sapropterin dihydrochloride is and how it works
Sapropterin dihydrochloride is a synthetic form of tetrahydrobiopterin (BH4). It helps the enzyme phenylalanine hydroxylase work more effectively to lower phenylalanine (Phe) levels in the body. (1)
Kuvan is used with a Phe-restricted diet to reduce blood Phe levels in adults and children aged 1 month and older with hyperphenylalaninemia due to BH4-responsive phenylketonuria.
Mechanism of action: how sapropterin dihydrochloride works
Sapropterin is a synthetic form of BH4 that helps phenylalanine hydroxylase work more effectively to lower Phe levels in the body. (1)
What sapropterin dihydrochloride is used for
BH4-responsive phenylketonuria
Kuvan is indicated to reduce blood phenylalanine levels in adult and pediatric patients aged 1 month and older with hyperphenylalaninemia due to BH4-responsive phenylketonuria. It is used in conjunction with a Phe-restricted diet. (1)
Before taking sapropterin dihydrochloride
Do not take / not appropriate for
- The supplied label reports no contraindications. (Kuvan) (1)
Tell your clinician about
- Any previous hypersensitivity reaction, including anaphylaxis or rash.
- Any symptoms that could suggest esophageal or stomach inflammation.
- Any seizure history, neurologic symptoms, or use of levodopa.
- Use of folate synthesis inhibitors, including methotrexate, valproic acid, phenobarbital, or trimethoprim.
- Use of a PDE-5 inhibitor, including sildenafil, tadalafil, or vardenafil.
- Pregnancy, plans for pregnancy, or breastfeeding.
How to take sapropterin dihydrochloride
- Take sapropterin with meals, preferably at consistent times.
- The prescribing clinician should determine the dose from age, body weight, blood Phe response, and the current product information.
- For children aged 1 month to 6 years, the label starting dose is 10 mg/kg once daily.
- For patients aged 7 years and older, the label starting-dose range is 10 to 20 mg/kg once daily.
- The label dose-adjustment range is 5 to 20 mg/kg daily based on blood Phe response.
- Use sapropterin together with the prescribed Phe-restricted diet. Do not make dose or diet changes without direction from the responsible clinical team.
Procedures and treatment changes
Tell the treating team before surgery, procedures, or any medicine change. Do not alter treatment without the responsible clinician. (1)
Missed dose
Specific missed-dose instructions were not established in the supplied research notes. Contact the prescribing clinician or pharmacist for advice; do not take an extra dose without their direction.
Overdose
Specific overdose-management protocol details were not established in the supplied research notes. If more than the prescribed amount may have been taken, contact a poison-information service or seek urgent medical advice.
Side effects
Common adverse reactions reported in clinical trials occurred in at least 4% of patients. Blood Phe monitoring is important because excessively low Phe levels can also cause adverse effects.
Headache
What to notice: Head pain.
What to do: Reported as a common side effect in the reviewed FDA label information. (1)
Upper-airway symptoms
What to notice: Runny nose, pharyngolaryngeal pain, cough, or nasal congestion.
What to do: Reported as a common side effect in the reviewed FDA label information. (1)
Digestive symptoms
What to notice: Diarrhea or vomiting.
What to do: Reported as a common side effect in the reviewed FDA label information. (1)
Possible upper gastrointestinal inflammation
What to notice: Symptoms that could indicate esophagitis or gastritis.
What to do: Contact the prescribing team promptly for assessment. Untreated cases may cause strictures, ulcers, or bleeding. (1)
Hyperactivity or neurologic change
What to notice: Symptoms of hyperactivity, or seizures, over-stimulation, irritability, or another change in neurologic status, particularly with levodopa use.
What to do: Contact the prescribing clinician promptly for assessment. (1)
Low phenylalanine level
What to notice: Low Phe levels identified through blood monitoring; children under 7 years receiving 20 mg/kg/day have an increased risk.
What to do: The clinical team should review blood Phe results and treatment requirements. (1)
Serious warnings
Anaphylaxis or hypersensitivity reaction — emergency
Symptoms: Symptoms of a serious allergic reaction, including anaphylaxis or rash. Most reported hypersensitivity reactions occurred within several days of treatment initiation.
Action: Seek emergency medical care for suspected anaphylaxis. The clinician providing care should determine whether treatment should be continued or discontinued and initiate appropriate medical treatment. (1)
Upper gastrointestinal inflammation — serious
Symptoms: Possible symptoms of esophagitis or gastritis.
Action: Seek prompt medical assessment. Untreated esophagitis or gastritis may cause strictures, ulcers, or bleeding. (1)
Interactions
| Medicine or test | Effect | Action |
|---|---|---|
| Levodopa | Seizures, over-stimulation, or irritability may occur. | The clinician should monitor for a change in neurologic status. (1) |
| Folate synthesis inhibitors | Methotrexate, valproic acid, phenobarbital, and trimethoprim may decrease endogenous BH4. | The clinical team should monitor blood Phe levels more frequently. (1) |
| PDE-5 inhibitors | Sildenafil, tadalafil, and vardenafil may have potential vasorelaxation effects when used with sapropterin. | The clinical team should monitor blood pressure. (1) |
Pregnancy, breastfeeding, kidney/liver function, age
Infants, children, and adolescents
Kuvan is indicated for pediatric patients from 1 month of age. Frequent blood Phe monitoring is especially important in pediatric patients. Children under 7 years receiving 20 mg/kg/day have an increased risk of low Phe levels. (1)
Pregnancy
Uncontrolled maternal blood Phe levels above 600 micromol/L are associated with severe teratogenic effects. The label states that blood Phe concentrations should be maintained between 120 and 360 micromol/L during pregnancy and during the 3 months before conception. Discuss pregnancy planning and Phe monitoring with the responsible clinical team. (1)
Breastfeeding
There are insufficient data on whether sapropterin is present in breast milk. The label reports 13 infants exposed through breastfeeding with no safety concerns reported. Discuss breastfeeding with the prescribing clinician. (1)
Monitoring
Before starting
- Confirm hyperphenylalaninemia due to BH4-responsive phenylketonuria and the need for a Phe-restricted diet.
- Establish blood Phe monitoring and review all medicines, including levodopa, folate synthesis inhibitors, and PDE-5 inhibitors.
- For people planning pregnancy, review the required blood Phe concentration target and monitoring plan.
During treatment
- Monitor blood Phe frequently; this is essential, especially in pediatric patients, to prevent neurologic damage from elevated Phe or adverse effects from excessively low Phe levels.
- Evaluate blood Phe response for up to 1 month at the starting dose. If there is no response at 10 mg/kg, the label describes increasing to 20 mg/kg for another month; treatment decisions must be made by the prescriber.
- The label describes treatment discontinuation if there is no biochemical response after 1 month at 20 mg/kg; this decision must be made by the responsible clinician.
- Monitor for hypersensitivity reactions, esophagitis, gastritis, hyperactivity, neurologic changes with levodopa, and blood-pressure effects with PDE-5 inhibitors.
- Monitor blood Phe more frequently when folate synthesis inhibitors are used.
Storage
Specific storage instructions were not established in the supplied research notes. Follow the current product packaging and pharmacist's instructions.
Professional information
Clinician-facing context only. Use the current local product information, blood Phe monitoring plan, Phe-restricted diet requirements, and individual clinical assessment.
United States
Indication: Hyperphenylalaninemia due to BH4-responsive phenylketonuria
Dose summary: For patients aged 1 month to 6 years, the label starting dose is 10 mg/kg once daily. For patients aged 7 years and older, the label starting-dose range is 10 to 20 mg/kg once daily. Administer with meals, preferably at consistent times. The dose-adjustment range is 5 to 20 mg/kg daily based on blood Phe response. Evaluate for up to 1 month at the starting dose; if no response occurs at 10 mg/kg, the label describes 20 mg/kg for a further month. The label directs discontinuation after no biochemical response following 1 month at 20 mg/kg.
Renal context: No specific renal-impairment dosing adjustment guidance was found in the supplied research notes. (1)
Hepatic guidance
No specific hepatic-impairment dosing adjustment guidance was found in the supplied research notes.
Overdose note
No specific overdose-management protocol details were found in the supplied research notes. (1)
Frequently asked questions
Is sapropterin used on its own for PKU?
No. Kuvan is used in conjunction with a Phe-restricted diet for people with hyperphenylalaninemia due to BH4-responsive PKU. (1)
Why are blood phenylalanine tests needed during treatment?
Frequent blood Phe monitoring is essential, especially in children, to prevent neurologic damage from elevated Phe and adverse effects from excessively low Phe levels. (1)
What should I do if I develop symptoms of a serious allergic reaction?
Seek emergency medical care for suspected anaphylaxis. The clinician providing care should advise on further treatment decisions. (1)
What is the mechanism of action of sapropterin dihydrochloride?
Sapropterin is a synthetic form of BH4 that helps phenylalanine hydroxylase work more effectively to lower Phe levels in the body. (1)
What is the generic name of Sapropterin dihydrochloride?
The generic name is sapropterin dihydrochloride. It is sold under brand names including Kuvan. (1)
What class of drug is sapropterin dihydrochloride?
Sapropterin dihydrochloride is classed as: Synthetic form of tetrahydrobiopterin (BH4); phenylalanine hydroxylase activator. (1)
References
- KUVAN (sapropterin dihydrochloride) tablet, soluble / powder, for solutionU.S. Food and Drug Administration (DailyMed) · United States · accessed 2026-08-05 · source 1
- SAPROPTERIN DIHYDROCHLORIDE TABLET [HIKMA PHARMACEUTICALS USA INC.] — US prescribing information (DailyMed SPL)U.S. National Library of Medicine (DailyMed) · US · accessed 2026-08-14 · source 2
- Sapropterin — patient drug information (MedlinePlus)U.S. National Library of Medicine (MedlinePlus) · US · accessed 2026-08-14 · source 3
- Sapropterin Dihydrochloride — FDA approval record (Drugs@FDA ANDA216797)U.S. Food and Drug Administration · US · accessed 2026-08-14 · source 4
- sapropterin dihydrochloride — RxNorm normalized drug concept (RXCUI 753340)U.S. National Library of Medicine (RxNorm) · US · accessed 2026-08-14 · source 5
Brand names by country
Single-ingredient sapropterin dihydrochloride names are shown separately by country. Product availability, strengths, and supply rules can change; combination products are not included here.
Priority countries
United States
- JAVYGTOR500 mg, 100 mg · dr. reddys laboratories inc
- Kuvan100 mg, 500 mg · biomarin pharmaceutical inc.
- ZELVYSIA100 mg, 500 mg · aucta pharmaceuticals, inc.
Canada
- KUVAN